• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Duavee (conjugated estrogens/bazedoxifene)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Duavee (conjugated estrogens/bazedoxifene)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Duavee pairs conjugated estrogens with bazedoxifene. Bazedoxifene (TSE-424) is a selective estrogen receptor modulator (SERM) designed to mimic the beneficial qualities of estrogens, while blocking estrogen in tissues where it can be harmful. The pairing of conjugated estrogens with bazedoxifene produces a composite effect that is specific to each target tissue.

    Duavee is specifically indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause and the prevention of postmenopausal osteoporosis.

    Duavee is supplied as a tablet for oral administration. The recommended dose is one tablet once a day.

    Clinical Results

    FDA Approval
    The FDA approval of Duavee was based on the following clinical trials:
    Moderate to Severe Vasomotor Symptoms Associated with Menopause
    A double blind, randomized placebo controlled trial enrolled 318 women ages 42 to 64 with at least 7 moderate to severe hot flashes per day or 50 per week at baseline. Duavee significantly reduced the number and severity of moderate to severe hot flushes, as measured by the daily severity score, compared with placebo at Weeks 4 and 12.
    Prevention of Postmenopausal Osteoporosis
    Two studies were conducted: Study 1 and 2. Study 1 was a 24-month, double-blind, randomized, placebo- and active-controlled study evaluating the safety and efficacy of multiple combinations of conjugated estrogen/bazedoxifene (including conjugated estrogens 0.45 mg/bazedoxifene 20 mg) compared to placebo. A total of 3,397 women were enrolled. Duavee significantly increased lumbar spine bone mineral density (BMD) at 24 months compared to placebo. Duavee also significantly increased total hip BMD. The treatment difference (or difference from placebo) in total hip BMD at 24 months was 1.96% (Duavee minus placebo) in women who had been postmenopausal between 1 and 5 years and 1.73% (Duavee minus placebo) in women who had been postmenopausal for more than 5 years. Study 2 was a 12-month, double-blind, randomized, placebo- and active-controlled study. Duavee significantly increased mean lumbar spine BMD (treatment difference, 1.51%), at 12 months compared to placebo in women who had been postmenopausal between 1 and 5 years. Treatment with Duavee also increased total hip BMD. The treatment difference in total hip BMD at 12 months was 1.21%. The effect of Duavee on endometrial hyperplasia and endometrial malignancy were also assessed in Study 1 and Study 2. By endometrial biopsy, the incidence of endometrial hyperplasia or malignancy for Duavee was below 1% in both studies.

    Side Effects

    Adverse events associated with the use of Duavee may include, but are not limited to, the following:

    • muscle spasms
    • nausea
    • diarrhea
    • dyspepsia
    • abdominal pain
    • oropharyngeal pain
    • dizziness
    • neck pain

    Mechanism of Action

    Duavee pairs conjugated estrogens with bazedoxifene. Conjugated estrogens and bazedoxifene function by binding to and activating estrogen receptors (ER) a and ß, which vary in proportion from tissue to tissue. Conjugated estrogens are composed of multiple estrogens and are agonists of ER- a and ß. Bazedoxifene is an estrogen agonist/antagonist that acts as an agonist in some estrogen-sensitive tissues and an antagonist in others. The pairing of conjugated estrogens with bazedoxifene produces a composite effect that is specific to each target tissue. The bazedoxifene component reduces the risk of endometrial hyperplasia that can occur with the conjugated estrogens component.

    Additional Information

    For additional information regarding Duavee or vasomotor symptoms associated with menopause and the prevention of postmenopausal osteoporosis, please visit the Duavee web page.

    Approval Date: 2013-10-01
    Company Name: Pfizer
    Back to Listings

    Upcoming Events

    • 26Jan

      Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

    • 27Jan

      Medical Device Clinical Trials in China: Latest Regulatory Developments

    • 11Feb

      Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

    • 23Mar

      Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

    • 26Apr

      MAGI's Clinical Research vConference — Spring 2021

    Featured Products

    • Regenerative Medicine – Steps to Accelerate Development : PDF

      Regenerative Medicine: Steps to Accelerate Development

    • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

      Clinical Trial Agreements: A Guide to Key Words and Phrases

    Featured Stories

    • Resources-360x240.png

      Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

    • FocusinRed-360x240.png

      Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

    • VaccinewithNeedle-360x240.png

      2021 Vaccine Industry Will Continue to be Dominated by COVID-19 Trials, Experts Say

    • Dominate-360x240.png

      COVID-19, Oncology, CNS and Infectious Disease Trials Will Dominate in 2021, Survey Predicts

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing